Sorafenib combined with chemotherapy and donor lymphocyte infusion as salvage therapy in patients with FLT3-positive acute myeloid leukemia relapse after allogeneic hematopoietic stem cell transplantation
10.3760/cma.j.issn.0578-1426.2018.05.009
- VernacularTitle:索拉非尼联合化疗、供者淋巴细胞输注挽救性治疗FLT3阳性急性髓系白血病异基因造血干细胞移植后复发
- Author:
Li XUAN
1
;
Zhiping FAN
;
Yu ZHANG
;
Na XU
;
Jieyu YE
;
Xuan ZHOU
;
Zhixiang WANG
;
Jing SUN
;
Qifa LIU
;
Fen HUANG
Author Information
1. 南方医科大学南方医院血液科
- Keywords:
Acute myeloid leukemia;
Allogeneic hematopoietic stem cell transplantation;
FMS-like tyrosine kinase 3;
Relapse;
Sorafenib;
Donor lymphocyte infusion
- From:
Chinese Journal of Internal Medicine
2018;57(5):351-354
- CountryChina
- Language:Chinese
-
Abstract:
To explore the efficacy of sorafenib combined with chemotherapy and donor lymphocyte infusion (DLI) in patients with FLT3-positive acute myeloid leukemia (AML) relapsed after allogeneic hematopoietic stem cell transplantation (allo-HSCT).Of the 14 patients relapsed after allo-HSCT,9 achieved complete remission after salvage therapy of sorafenib combined with chemotherapy and DLI,6 with complete molecular remission,2 with partial remission,and 3 with no response.With a median follow up of 220 (range,30-1 782) days after post-transplantation relapse,7 patients were still alive and 7 died.Salvage therapy of sorafenib combined with chemotherapy and DLI shows a decent therapeutic effect for FLT3-positive AML relapsed after allo-HSCT.
